KR20180032587A - 디곡신의 미세화를 위한 비기계적 공정 - Google Patents
디곡신의 미세화를 위한 비기계적 공정 Download PDFInfo
- Publication number
- KR20180032587A KR20180032587A KR1020187003325A KR20187003325A KR20180032587A KR 20180032587 A KR20180032587 A KR 20180032587A KR 1020187003325 A KR1020187003325 A KR 1020187003325A KR 20187003325 A KR20187003325 A KR 20187003325A KR 20180032587 A KR20180032587 A KR 20180032587A
- Authority
- KR
- South Korea
- Prior art keywords
- digoxin
- concentrated
- precipitate
- solution
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 title claims abstract description 68
- 229960005156 digoxin Drugs 0.000 title claims abstract description 68
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 title claims abstract description 68
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 238000010297 mechanical methods and process Methods 0.000 title description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 24
- 239000002244 precipitate Substances 0.000 claims abstract description 17
- 230000008569 process Effects 0.000 claims abstract description 14
- 239000007857 degradation product Substances 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000003791 organic solvent mixture Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 239000011541 reaction mixture Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 238000009826 distribution Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 240000001879 Digitalis lutea Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178009.5 | 2015-07-23 | ||
| EP15178009.5A EP3120839B1 (en) | 2015-07-23 | 2015-07-23 | Non-mechanical process for the micronization of digoxin |
| PCT/IB2016/001035 WO2017013485A1 (en) | 2015-07-23 | 2016-07-21 | Non-mechanical process for the micronization of digoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180032587A true KR20180032587A (ko) | 2018-03-30 |
Family
ID=54010825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187003325A Ceased KR20180032587A (ko) | 2015-07-23 | 2016-07-21 | 디곡신의 미세화를 위한 비기계적 공정 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180207099A1 (enExample) |
| EP (2) | EP3120839B1 (enExample) |
| JP (1) | JP6814522B2 (enExample) |
| KR (1) | KR20180032587A (enExample) |
| CN (1) | CN108024963A (enExample) |
| AU (1) | AU2016296162B2 (enExample) |
| ES (2) | ES2716681T3 (enExample) |
| HU (2) | HUE042420T2 (enExample) |
| MX (1) | MX365906B (enExample) |
| PL (2) | PL3120839T3 (enExample) |
| PT (2) | PT3120839T (enExample) |
| WO (1) | WO2017013485A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110632B (zh) * | 2018-10-31 | 2023-01-20 | 上海上药信谊药厂有限公司 | 一种地高辛气雾剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3643760A1 (de) * | 1986-12-20 | 1988-06-23 | Boehringer Mannheim Gmbh | Verfahren zur anreicherung und/oder isolierung von herzglykosiden unter verwendung unpolarer adsorberharze |
| WO2003007968A1 (en) | 2001-07-17 | 2003-01-30 | Sun Pharmaceutical Industries Ltd. | A cardiotonic composition |
| CN101390838A (zh) * | 2008-10-10 | 2009-03-25 | 北京工业大学 | 一种制备微粉化药物的方法 |
-
2015
- 2015-07-23 PL PL15178009T patent/PL3120839T3/pl unknown
- 2015-07-23 HU HUE15178009A patent/HUE042420T2/hu unknown
- 2015-07-23 ES ES15178009T patent/ES2716681T3/es active Active
- 2015-07-23 EP EP15178009.5A patent/EP3120839B1/en active Active
- 2015-07-23 PT PT15178009T patent/PT3120839T/pt unknown
-
2016
- 2016-07-21 WO PCT/IB2016/001035 patent/WO2017013485A1/en not_active Ceased
- 2016-07-21 AU AU2016296162A patent/AU2016296162B2/en not_active Ceased
- 2016-07-21 ES ES16754316T patent/ES2765675T3/es active Active
- 2016-07-21 EP EP16754316.4A patent/EP3324942B1/en active Active
- 2016-07-21 JP JP2018503128A patent/JP6814522B2/ja not_active Expired - Fee Related
- 2016-07-21 HU HUE16754316A patent/HUE048065T2/hu unknown
- 2016-07-21 PT PT167543164T patent/PT3324942T/pt unknown
- 2016-07-21 MX MX2018001010A patent/MX365906B/es active IP Right Grant
- 2016-07-21 CN CN201680042406.3A patent/CN108024963A/zh active Pending
- 2016-07-21 PL PL16754316T patent/PL3324942T3/pl unknown
- 2016-07-21 US US15/746,697 patent/US20180207099A1/en not_active Abandoned
- 2016-07-21 KR KR1020187003325A patent/KR20180032587A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001010A (es) | 2018-05-17 |
| HUE048065T2 (hu) | 2020-05-28 |
| EP3120839B1 (en) | 2018-12-19 |
| MX365906B (es) | 2019-06-18 |
| PT3324942T (pt) | 2020-01-17 |
| AU2016296162A1 (en) | 2018-02-01 |
| HUE042420T2 (hu) | 2019-07-29 |
| US20180207099A1 (en) | 2018-07-26 |
| BR112018001204A2 (pt) | 2018-09-11 |
| JP6814522B2 (ja) | 2021-01-20 |
| PT3120839T (pt) | 2019-03-25 |
| JP2018521073A (ja) | 2018-08-02 |
| WO2017013485A1 (en) | 2017-01-26 |
| ES2765675T3 (es) | 2020-06-10 |
| PL3120839T3 (pl) | 2019-08-30 |
| ES2716681T3 (es) | 2019-06-14 |
| PL3324942T3 (pl) | 2020-05-18 |
| EP3324942A1 (en) | 2018-05-30 |
| AU2016296162B2 (en) | 2021-03-18 |
| CN108024963A (zh) | 2018-05-11 |
| EP3324942B1 (en) | 2019-10-30 |
| EP3120839A1 (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014169341A (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| WO2010109961A1 (ja) | アルクチゲニン高含有ゴボウシエキス及びその製造方法 | |
| US9849090B2 (en) | Pharmaceutical compositions of rifaximin | |
| CN109988104B (zh) | 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途 | |
| KR101197277B1 (ko) | 경구용 결핵의 치료용 또는 예방용 고형 제형 | |
| KR20180032587A (ko) | 디곡신의 미세화를 위한 비기계적 공정 | |
| EP2359816A1 (en) | Aripiprazole formulations | |
| CA2471651C (en) | Amorphous substance of tricyclic triazolobenzazepine derivative | |
| EP3834821B1 (en) | Dropping pill comprising ginkgo terpene lactones as active components and preparation method therefor | |
| KR101760278B1 (ko) | 에페리손을 유효 성분으로 함유하는 서방성 미립구의 제조방법 | |
| DE102008000351B4 (de) | Verfahren zur Herstellung eines Ebastin enthaltenden Granulats sowie einer festen pharmazeutischen Zusammensetzung, Ebastin enthaltendes Granulat und dessen Verwendung | |
| KR102760108B1 (ko) | 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제 | |
| EP4410278A1 (en) | Pharmaceutical composition comprising enavogliflozin | |
| KR100905203B1 (ko) | 애엽추출물 함유 필름코팅정제 | |
| BR112018001204B1 (pt) | Processo não-mecânico para a micronização da digoxina | |
| KR20240011049A (ko) | 천연 추출물의 고체분산체 및 이의 제조방법 | |
| WO2023283418A1 (en) | Prenylated chalcone and flavonoid compositions for use in treating cancer | |
| CN114681465A (zh) | 洛铂-黄酮药物共晶及其制备方法和应用 | |
| KR20080035294A (ko) | 1,2-디[2-메톡시-4-(2-카르복실비닐)]페녹시에탄 화합물을유효성분으로 함유하는 파킨슨병 예방 및 치료용 약학적조성물 | |
| JP2005200332A (ja) | アリルカテコール系化合物を有効成分とする抗マラリア組成物 | |
| JP2004210766A (ja) | ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の新規結晶の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180202 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210129 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230405 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230711 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230405 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |